Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115

Active Not RecruitingPhase 3

Sponsor: Janssen Research & Development, LLC

Conditions: Plaque Psoriasis

Interventions: JNJ-77242113, Placebo

Countries: United States, Argentina, Australia, Canada, China, France, Germany, Hungary

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion Criteria:

* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
* Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study
Locations (170)
  • Phoenix, Arizona, United States
  • Fort Smith, Arkansas, United States
  • Fountain Valley, California, United States
  • Fremont, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Santa Ana, California, United States
  • Santa Monica, California, United States
  • Miami, Florida, United States
  • North Miami Beach, Florida, United States
  • Tampa, Florida, United States
  • Macon, Georgia, United States
  • Rolling Meadows, Illinois, United States
  • Skokie, Illinois, United States
  • West Dundee, Illinois, United States
  • Indianapolis, Indiana, United States
  • Plainfield, Indiana, United States
  • Owensboro, Kentucky, United States
  • Lake Charles, Louisiana, United States
  • Beverly, Massachusetts, United States
  • Clarkston, Michigan, United States
  • New Brighton, Minnesota, United States
  • Omaha, Nebraska, United States
  • Portsmouth, New Hampshire, United States
  • East Windsor, New Jersey, United States
  • New York, New York, United States
  • Wilmington, North Carolina, United States
  • Athens, Ohio, United States
  • Boardman, Ohio, United States
  • Fairborn, Ohio, United States
  • + 140 more on CT.gov